Review

Annual Influenza Vaccination: Offering Protection Beyond Infection

Authors: Kelly C. Rogers, PharmD, Juliet P. Wallace, PharmD, Stephan L. Foster, PharmD, Shannon W. Finks, PharmD

Abstract

Cardiovascular disease (CVD), the leading cause of death in the world, is largely preventable. An increasing amount of evidence suggests that annual vaccination with inactivated influenza vaccine reduces morbidity and mortality associated with CVD; however, immunization rates in patients with CVD fall consistently below the goals established by Healthy People 2020. This review outlines the importance of vaccination and summarizes the available literature on the role of seasonal influenza vaccination and the incidence of coronary artery disease and stroke.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation 2011; 123: e18–e209.
 
2. US Department of Health and Human Services. Healthy People 2020: immunization and infectious diseases. http://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=23. Accessed June 13, 2011.
 
3. Health, United States, 2010: With Special Feature on Death and Dying. Hyattsville, MD: US Public Health Service; 2011.
 
4. Madjid M, Alfred A, Sahai A, et al. Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease. Tex Heart Inst J 2009; 36: 546–552.
 
5. Public Health Weekly Reports for November 11, 1932. Public Health Rep 1932; 47: 2159–2189.
 
6. de Diego C, Vila-Corcoles A, Ochoa O, et al. Effects of annual influenza vaccination on winter mortality in elderly people with chronic heart disease. Eur Heart J 2009; 30: 209–216.
 
7. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007; 28: 1205–1210.
 
8. Madjid M, Naghavi M, Litovsky S, et al. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 2003; 108: 2730–2736.
 
9. Naghavi M, Wyde P, Litovsky S, et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 2003; 107: 762–768.
 
10. Bouwman JJ, Visseren FL, Bosch MC, et al. Procoagulant and inflammatory response of virus-infected monocytes. Eur J Clin Invest 2002; 32: 759–766.
 
11. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis 2009; 9: 601–610.
 
12. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 2001; 103: 2283–2288.
 
13. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002; 106: 1127–1132.
 
14. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611–2618.
 
15. Gurfinkel EP, de la Fuente RL, Mendiz O, et al. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105: 2143–2147.
 
16. Gurfinkel EP, Leon de la Fuente R, Mendiz O, et al. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J 2004; 25: 25–31.
 
17. Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Tex Heart Inst J 2004; 31: 28–32.
 
18. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 2008; 29: 1350–1358.
 
19. Phrommintikul A, Kuanprasert S, Wongcharoen W, et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011; 32: 1730–1735.
 
20. Gwini SM, Coupland CAC, Siriwardena AN. The effect of influenza vaccination on risk of acute myocardial infarction: self-controlled case-series study. Vaccine 2011; 29: 1145–1149.
 
21. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, pneumococcal vaccination and risk of acute myocardial infarction: matched case-control study. Can Med Assoc J 2010; 182: 1617–1623.
 
22. Mansur Ade P, Favarato D, Ramires JA. Vaccination against the influenza virus and mortality due to cardiovascular diseases in the city of Sao Paulo. Arq Bras Cardiol 2009; 93: 395–399, 87-91.
 
23. Wang CS, Wang ST, Lai CT, et al. Impact of influenza vaccination on major cause-specific mortality. Vaccine 2007; 25: 1196–1203.
 
24. Heffelfinger JD, Heckbert SR, Psaty BM, et al. Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin 2006; 2: 161–166.
 
25. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322–1332.
 
26. Siscovick DS, Raghunathan TE, Lin D, et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000; 152: 674–677.
 
27. Naghavi M, Barlas Z, Siadaty S, et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102: 3039–3045.
 
28. Jackson LA, Yu O, Heckbert SR, et al. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Vaccine Safety Datalink Study Group. Am J Epidemiol 2002; 156: 634–640.
 
29. Lavallee P, Perchaud V, Gautier-Bertrand M, et al. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002; 33: 513–518.
 
30. Grau AJ, Fischer B, Barth C, et al. Influenza vaccination is associated with a reduced risk of stroke. Stroke 2005; 36: 1501–1506.
 
31. Burney LE. Influenza immunization: statement. Public Health Rep 1960; 75: 944.
 
32. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59: 1–62.
 
33. Hak E, Buskens E, Nichol KL, et al. Do recommended high-risk adults benefit from a first influenza vaccination? Vaccine 2006; 24: 2799–2802.
 
34. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005; 165: 274–280.
 
35. Davis MM, Taubert K, Benin AL, et al. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation 2006; 114: 1549–1553.
 
36. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130–2139.
 
37. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388–391.
 
38. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517–584.
 
39. Egede LE, Zheng D. Racial/ethnic differences in influenza vaccination coverage in high-risk adults. Am J Public Health 2003; 93: 2074–2078.
 
40. Singleton JA, Wortley P, Lu PJ. Influenza vaccination of persons with cardiovascular disease in the United States. Tex Heart Inst J 2004; 31: 22–27.
 
41. Davis MM, Wortley PM, Ndiaye SM, et al. Influenza vaccine for high-risk non-elderly adults: a national survey of subspecialists. Hum Vaccin 2008; 4: 229–233.